Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.54 |
| ▸ | RAF1 | P04049 | 9/20 | 0.51 |
| ▸ | BRAF | P15056 | 9/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | GBA1 | P04062 | 5/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14349125 | 0.86 | MCHR1 (0.49) | TACR1MCHR1RAF1BRAFMEN1 | |
| SCHEMBL5654093 | 0.85 | GBA1 (0.61) | RAB9AGBA1GLANPC1KDM4E | |
| SCHEMBL14349133 | 0.83 | MCHR1 (0.47) | TACR1MCHR1RAF1BRAFMEN1 | |
| SCHEMBL14349131 | 0.83 | TACR1 (0.68) | TACR1 | |
| SCHEMBL4761189 | 0.83 | TACR1 (0.51) | TACR1MCHR1RAF1BRAFMEN1 | |
| SCHEMBL14349128 | 0.82 | MCHR1 (0.50) | TACR1MCHR1RAF1BRAFMEN1 | |
| SCHEMBL14349130 | 0.82 | MCHR1 (0.46) | TACR1MCHR1RAF1BRAFMEN1 | |
| SCHEMBL1399432 | 0.81 | TACR1 (0.70) | TACR1RAF1BRAF | |
| SCHEMBL14349129 | 0.80 | GPBAR1 (0.56) | TACR1MCHR1RAF1BRAF | |
| SCHEMBL5653881 | 0.78 | ALDH1A1 (0.56) | MEN1RAB9AKMT2AGBA1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293492-A1 | Quinoline Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2007-12-20 | — | — | US | disclosed |
| US-20070293492-A1 | Quinoline Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293492-A1 | Quinoline Tachykinin Receptor Antagonists | TACR1, TACR2, NPSR1 | TACR1 1/4885MCHR1 117/4885RAF1 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.